Physician profile
David A Barbie
NPI 1164401626
$204,545.22
in general payments reported to CMS, 2019-2025
13 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $30K · 2021: $28K · 2022: $32K · 2023: $30K · 2024: $37K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $95K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,700 · Travel and Lodging: $3,190 · Food and Beverage: $1,027 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $94,660.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,700.00 |
| Travel and Lodging | $3,190.41 |
| Food and Beverage | $1,026.63 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $138,000.00 | 2020-2025 | |
| Daiichi Sankyo INC. | $18,410.58 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $14,937.64 | 2019-2025 | |
| Gilead Sciences, INC. | $11,099.24 | 2019-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $7,134.49 | 2019-2023 | Keytruda |
| Pfizer INC. | $3,700.00 | 2025 | |
| Janssen Biotech, INC. | $2,937.50 | 2025 | Rybrevant |
| Chugai Pharmaceutical Co., Ltd. | $2,667.88 | 2022-2025 | Tecentriq |
| Abbvie INC. | $1,650.00 | 2020 | |
| Eli Lilly and Company | $1,600.00 | 2024 | |
| Emd Serono, INC. | $1,500.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $907.89 | 2023-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barbie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.